Regulatory News In Brief
Device reviewers miss some performance goals: FDA did not meet its fiscal 2008 goals for issuing decisions on certain device pre-market submissions, according to materials from FDA's latest quarterly update to industry. Federal law requires FDA to endeavor to reach a decision on 60% of pre-market approval submissions and panel-track PMA supplements within 180 days, and on 90% of PMAs and panel-track supplements within 295 days. In FY 2008, CDRH made decisions on 23 of 33 PMAs and panel-track supplement submissions. Some decisions are still pending, but in the best-case scenario, the center will miss its 295-day performance goal, and may miss its 180-day goal, as well. CDRH also missed its performance goals for expedited PMAs and expedited panel-track supplements (50% of decisions within 180 days and 90% of decisions within 280 days). The center similarly missed its performance goals for PMA modules, but will meet its performance goal for 180-day supplements and real-time supplements. CDRH also met its goal for 510(k) decisions, reaching decisions on more than 90% of submissions within 90 days and more than 98% of submissions within 150 days. CDRH received 3,848 510(k)s in FY 2008 and 4,103 510(k)s in FY 2009. And signals indicate that reviews may be speeding up. Average time to a final decision on PMAs and panel-track supplements was 215 days in FY 2008 and 172 days in FY 2009. 510(k) decisions took about 112 days on average in FY 2008 and 88 days in FY 2009, FDA says
Keep up with the top medtech business and regulatory news.
More from Archive
A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.
REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.
St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.
Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.
More from Medtech Insight
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.